DOCSLIB.ORG

Roland R. Griffiths CV

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Roland R. Griffiths CV June 2020 CURRICULUM VITAE ROLAND R. GRIFFITHS EDUCATION: B.S. Occidental College 1968 Los Angeles, California Psychology (Honors) Ph.D. University of Minnesota 1972 Minneapolis, Minnesota Psychology (Major) Pharmacology (Minor) PUBLICATIONS BY AREAS OF SPECIALIZATION: Psychedelics Caffeine self-administration, withdrawal, subjective effects, and addiction Sedative self-administration and sedative effects Cigarette smoking and nicotine self-administration Alcohol self-administration Baboon drug self-administration and drug discrimination Miscellaneous All Publications ACADEMIC POSITIONS: 2019-present Director, Johns Hopkins Center for Psychedelic and Consciousness Research 1987-present Professor of Behavioral Biology Department of Psychiatry & Behavioral Sciences The Johns Hopkins University School of Medicine Baltimore, Maryland 1987-present Professor of Neuroscience Department of Neuroscience The Johns Hopkins University School of Medicine Baltimore, Maryland 1983-1986 Associate Professor of Neuroscience Department of Neuroscience The Johns Hopkins University School of Medicine 2 Back to Areas of Specialization Baltimore, Maryland 1978-1986 Associate Professor of Behavioral Biology Department of Psychiatry & Behavioral Sciences The Johns Hopkins University School of Medicine Baltimore, Maryland 1972-1978 Assistant Professor of Behavioral Biology Department of Psychiatry & Behavioral Sciences The Johns Hopkins University School of Medicine Baltimore, Maryland POSITIONS HELD: 1975-1984 Research Chief Department of Psychiatry Baltimore City Hospitals Baltimore, Maryland 1972-1975 Research Associate Department of Psychiatry Baltimore City Hospitals Baltimore, Maryland 1969-1972 Consultant in Behavior Modification Faribault State Hospital Faribault, Minnesota 1968-1972 USPHS Pre-doctoral Research Fellow, Psychopharmacology University of Minnesota Minneapolis, Minnesota 3 Back to Areas of Specialization POSTDOCTORAL FELLOWS SUPERVISED: L. DiAnne Bradford, 1976-1978; Jack E. Henningfield, 1978-1980; Nancy A. Ator, 1978-1982; Scott E. Lukas (co-mentored with J.V. Brady), 1979-1982; Daniel R. McLeod (co-mentored with G.E. Bigelow), 1981-1982; Larry D. Chait, 1981-1982; Rosemarie V. Nemeth-Coslett, 1982-1984; Richard J. Lamb, 1983-1986; John D. Roache, 1983-1985; Stephen T. Higgins, 1983-1985; Warren K. Bickel, 1984-1985; William T. Kirk, 1985-1987; Phillip P. Woodson, 1985-1987; Martin Y. Iguchi, 1986- 1988; Suzette M. Evans, 1987-1990; Christine A. Sannerud, 1987-1989; Eric C. Strain, 1988-1990; John G. Guarino, 1988-1989; Barbara Wolfe, 1988-1989; Thomas S. Critchfield, 1989-1990; Kenneth Silverman, 1989-1991; Barbara J. Kaminski, 1990-1992; Joseph R. Troisi II, 1990-1992; Geoffrey K. Mumford, 1991- 1992; Craig R. Rush, 1992-1994; Elise M. Weerts, 1993-1995; Mary E. Abreu, 1993-1994; Joseph M. Frey, 1993-1996; Katherine Bonson, 1995-1996; Bridgette E. Garrett, 1995-1997; Miriam Mintzer, 1995-1998; Ellen Nann-Vernotica, 1997-1998; Hendrée Jones, 1997-1998; Brandi Smith, 1998-2000; Xiao Sobel, 1999-2001; Allison L. Chausmer 2000-2002; Laura M. Juliano 2001-2002. Patricia Suess, 2002- 2004; Stacey Sigmon, 2002-2004; Darlene E. Crone-Todd, 2002-2003; Brian Richards, 2002-2006; Matthew Johnson, 2004-2007; Lawrence Carter, 2005-2007; Chad Reissig, 2006-2009; Angela Duke, 2008-2011; Daniel Evatt, 2009-2012; Katherine MacLean, 2009-2012; Matthew Bradstreet, 2012-2013; Steven Meredith, 2012-2014; Albert Garcia-Romeu, 2012-2016; Frederick Barrett, 2013-2016; Theresa Carbonaro 2013-2017; Mary Sweeney, 2014-2018; Darrick May, 2015- 2018; Alan Davis, 2017-2019; Manoj Doss, 2018-present; Natalie Gukasyan, 2019- present; David Yaden, 2020-present. MEMBERSHIP IN SOCIETIES AND PROFESSIONAL ORGANIZATIONS: Behavioral Pharmacology Society American Psychological Association - Fellow Division of Psychopharmacology Division of the Experimental Analysis of Behavior American Association for the Advancement of Science ISGIDAR - International Study Group Investigating Drugs as Reinforcers. President 1977 and 1978. American College of Neuropsychopharmacology - Fellow The College on Problems of Drug Dependence - Executive Committee 1983-1987; 1991-1995. Heffter Research Institute – Board of Directors 2010-present. CERTIFICATION: Maryland State Board of Examiners of Psychologists, 1975-present. National Register of Health Care Providers in Psychology, 1978-present. JOURNAL EDITOR/EDITORIAL BOARD: Behavioural Pharmacology - Editorial Board 1989-2010 Journal of Psychopharmacology - Editorial Advisory Board 1990-present Pharmacology Biochemistry and Behavior - Editorial Advisory Board 1989-2015 Journal of Studies on Alcohol - Behavioral Pharmacology 4 Back to Areas of Specialization Field Editor 1983-1992 Drug and Alcohol Dependence - Board of Editors 1985-1991 Journal of Caffeine Research – Board of Editors 2011-present CONSULTANT: National Institutes of Health: Consultant for NIDA reviewing research contracts, grants and reports 1977-1992; Committee member on NIDA Clinical and Behavioral Research Subcommittee Study Section 1982-1987; NIDA Medication Development Program: NIDA Ad Hoc Consultants Panel 1996-1997; NIH Study Section BBBP-01 1999-2000; NIH Study Section ZRG1 SSS-C Predoctoral Fellowship Reviews 2002; NIH Study Sections, 2004, 2005. Food and Drug Administration: Subcommittee on Guidelines for Animal and Human Abuse Liability Testing, Drug Abuse Advisory Committee, 1990; Member, Drug Abuse Advisory Subcommittee, 2008-present World Health Organization: Invited participant for WHO 5th, 6th, and 8th Reviews of Psychoactive Substances for International Control - Benzodiazepines, Geneva, 1981, 1982, 1983; Invited participant in jointly sponsored WHO-U.S.S.R. review of use of psychotropic drugs with special emphasis on tranquilizers, Moscow, 1986; Consultant, WHO review of nonbarbiturate sedatives and benzodiazepines for international control, 1986, 1987; Consultant for preparation of WHO review document on benzodiazepines for international control, 1989 and 1990; Invited participant in 27th Expert Committee on Drug Dependence, Geneva, 1989, 1990; WHO Expert Advisory Panel on Drug Dependence and Alcohol Problems, 1995- 1998; Invited participant in 32nd Expert Committee on Drug Dependence, Geneva, 2000; WHO Expert Advisory Panel on Drug Dependence (Dependence Liability Evaluation), 1998-present Office on Smoking and Health: Invited participant for Working Meeting on Research Needs on Low Yield Cigarettes, 1980, resulting in a report of the Surgeon General: "The Health Consequences of Smoking: The Changing Cigarette", 1981. Consultant for the 1988 report of the Surgeon General: "The Health Consequences of Smoking: Nicotine Addiction." Drug Enforcement Administration: Consultant for a hearing of the Drug Abuse Advisory Committee of the Food and Drug Administration on the rescheduling of phentermine, phendimetrazine and diethylpropion, November 1980 5 Back to Areas of Specialization Pharmaceutical Industry: Occasional consultant for CIBA Pharmaceutical Company (1986; 1991-1993), The Upjohn Company (1986; 1991-1995), A.H. Robins Company (1986-1990), Roche Laboratories (1987-1990), Lorex Pharmaceuticals (1987-1990), Schering AG (1988-1992), Pfizer Pharmaceuticals (1988-1994), Stuart Pharmaceuticals (1990), Wyeth Laboratories (1986), Synthélabo Researche Imidazopyridine Advisory Board (1991-1993), Searle (1991; 1993; 1997), Sandoz (1991-1994), American Cyanamid Co./Lederle Laboratories (1992, 1993-1995), Alza Corporation (1992), McNeil Consumer Products Company (1993), Zeneca Pharmaceuticals (1993), TAP Pharmaceuticals Inc. (1992-1994), Fisons Pharmaceuticals (1995); Bristol-Myers Squibb (1995), H. Lundbeck A/C (1995-1997), Wyeth-Ayerst Research (1995-1998), Astra Charnwood (1996); Proctor & Gamble Company (1996); G.D. Searle & Co. (1997); Cephalon, Inc. (1997); Organon Inc. (1999-2000); Parke-Davis (2000); Ancile Pharmaceuticals (2000-2003); Neurocrine (2002-2004); Alexza (2002-2003); Pharmacia Corp. (2002-2003); Somaxon Pharmaceuticals (2005), Wyeth Pharmaceuticals (2003), Neurocrine (2002-2004), Abbott Laboratories (2005); Pfizer Inc (2002-2003); Novartis (2005); TransOral Pharmaceuticals (2004-2007); Forest Laboratories (2002); Takada Pharmaceuticals (2001-2005); Merck & Co. (2001-2009, 2010- present); Bristol-Myers Squibb (2006-present); Jazz Pharmaceuticals (2007- present); Alexza Pharmaceuticals (2007-present); Sanofi-Aventis US LLC (2008); Actelion Pharmaceuticals (2008); Hoffman-La Roche Inc. (2009-present); Transcept Pharmaceuticals (2009-present); Vanda Pharmaceuticals (2011- present). American Psychiatric Association: Task force on benzodiazepines, 1988-1990 AWARDS Solvay Award for Outstanding Basic Psychopharmacological Research on Affective Disorders. American Psychological Association Division 28, 1994. Brady/Schuster Award for Outstanding Behavioral Science Research in Psychopharmacology and Substance Abuse. American Psychological Association Division 28, 2002 Marian W. Fischman Award for Outstanding Research on Drug Dependence. Columbia University, 2010 Nathan B. Eddy Award for Outstating Research in Drug Dependence. College on Problems of Drug Dependence, 2015. 6 Back to Areas of Specialization Publications Organized Chronologically 1. Griffiths, R.R., Sears, B., & Jennings, L. (1969). Specificity of transfer of a learned response by intracisternal injection of brain extract from trained rats: Negative findings. Psychological Reports, 25, 339-348. PMID: 5367114 2. Bigelow, G., & Griffiths, R.R. (1972). An intensive teaching unit for severely
Load more

Recommended publications
  • WO 2017/145013 Al 31 August 2017 (31.08.2017) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/145013 Al 31 August 2017 (31.08.2017) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07D 498/04 (2006.01) A61K 31/5365 (2006.01) kind of national protection available): AE, AG, AL, AM, C07D 519/00 (2006.01) A61P 25/00 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, (21) Number: International Application DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/IB20 17/050844 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, (22) International Filing Date: KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, 15 February 2017 (15.02.2017) MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, (25) Filing Language: English RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, (26) Publication Language: English TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 62/298,657 23 February 2016 (23.02.2016) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant: PFIZER INC. [US/US]; 235 East 42nd Street, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, New York, New York 10017 (US).
    [Show full text]
  • Metabolism and Pharmacokinetics in the Development of New Therapeutics for Cocaine and Opioid Abuse
    University of Mississippi eGrove Electronic Theses and Dissertations Graduate School 2012 Metabolism And Pharmacokinetics In The Development Of New Therapeutics For Cocaine And Opioid Abuse Pradeep Kumar Vuppala University of Mississippi Follow this and additional works at: https://egrove.olemiss.edu/etd Part of the Pharmacy and Pharmaceutical Sciences Commons Recommended Citation Vuppala, Pradeep Kumar, "Metabolism And Pharmacokinetics In The Development Of New Therapeutics For Cocaine And Opioid Abuse" (2012). Electronic Theses and Dissertations. 731. https://egrove.olemiss.edu/etd/731 This Dissertation is brought to you for free and open access by the Graduate School at eGrove. It has been accepted for inclusion in Electronic Theses and Dissertations by an authorized administrator of eGrove. For more information, please contact [email protected]. METABOLISM AND PHARMACOKINETICS IN THE DEVELOPMENT OF NEW THERAPEUTICS FOR COCAINE AND OPIOID ABUSE A Dissertation presented in partial fulfillment of requirements for the degree of Doctor of Philosophy in Pharmaceutical Sciences in the Department of Pharmaceutics The University of Mississippi by PRADEEP KUMAR VUPPALA April 2012 Copyright © 2012 by Pradeep Kumar Vuppala All rights reserved ABSTRACT Cocaine and opioid abuse are a major public health concern and the cause of significant morbidity and mortality worldwide. The development of effective medication for cocaine and opioid abuse is necessary to reduce the impact of this issue upon the individual and society. The pharmacologic treatment for drug abuse has been based on one of the following strategies: agonist substitution, antagonist treatment, or symptomatic treatment. This dissertation is focused on the role of metabolism and pharmacokinetics in the development of new pharmacotherapies, CM304 (sigma-1 receptor antagonist), mitragynine and 7-hydroxymitragynine (µ-opioid receptor agonists), for the treatment of drug abuse.
    [Show full text]
  • A Role for Histone Modification in the Mechanism of Action of Antidepressant and Stimulant Drugs: a Dissertation
    University of Massachusetts Medical School eScholarship@UMMS GSBS Dissertations and Theses Graduate School of Biomedical Sciences 2007-12-28 A Role for Histone Modification in the Mechanism of Action of Antidepressant and Stimulant Drugs: a Dissertation Frederick Albert Schroeder University of Massachusetts Medical School Let us know how access to this document benefits ou.y Follow this and additional works at: https://escholarship.umassmed.edu/gsbs_diss Part of the Amino Acids, Peptides, and Proteins Commons, Cells Commons, Enzymes and Coenzymes Commons, Genetic Phenomena Commons, Mental Disorders Commons, Nervous System Commons, and the Therapeutics Commons Repository Citation Schroeder FA. (2007). A Role for Histone Modification in the Mechanism of Action of Antidepressant and Stimulant Drugs: a Dissertation. GSBS Dissertations and Theses. https://doi.org/10.13028/7bk0-a687. Retrieved from https://escholarship.umassmed.edu/gsbs_diss/370 This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in GSBS Dissertations and Theses by an authorized administrator of eScholarship@UMMS. For more information, please contact [email protected]. A Dissertation Presented by Frederick Albert Schroeder Submitted to the Faculty of the University of Massachusetts Graduate School of Biomedical Sciences Worcester, Massachusetts, USA in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY December 28, 2007 Program in Neuroscience A Role for Histone Modification in the Mechanism of Action of Antidepressant and Stimulant Drugs A Dissertation Presented By Frederick Albert Schroeder Approved as to style and content by: _____________________________________ Alonzo Ross, Ph.D., Chair of Committee _____________________________________ Pradeep Bhide, Ph.D., Member of Committee _____________________________________ Craig L.
    [Show full text]
  • Analysis of Consumption of Energy Drinks by a Group of Adolescent Athletes
    International Journal of Environmental Research and Public Health Article Analysis of Consumption of Energy Drinks by a Group of Adolescent Athletes Dariusz Nowak 1,* and Artur Jasionowski 2 1 Department of Nutrition and Dietetics, Faculty of Health Sciences, Nicolaus Copernicus University in Toru´n,Ludwik Rydygier Collegium Medicum in Bydgoszcz, D˛ebowa3, Bydgoszcz 85-626, Poland 2 Department of Theoretical Foundations of Biomedical Sciences and Medical Informatics, Faculty of Pharmacy, Nicolaus Copernicus University in Toru´n, Ludwik Rydygier Collegium Medicum in Bydgoszcz, D˛ebowa3, Bydgoszcz 85-626, Poland; [email protected] * Correspondence: [email protected]; Tel.: +48-525-855-401; Fax: +48-525-855-403 Academic Editor: María M. Morales Suárez-Varela Received: 28 April 2016; Accepted: 5 July 2016; Published: 29 July 2016 Abstract: Background: Energy drinks (EDs) have become widely popular among young adults and, even more so, among adolescents. Increasingly, they are consumed by athletes, particularly those who have just begun their sporting career. Uncontrolled and high consumption of EDs, in addition to other sources of caffeine, may pose a threat to the health of young people. Hence, our objective was to analyze the consumption of EDs among teenagers engaged in sports, including quantity consumed, identification of factors influencing consumption, and risks associated with EDs and EDs mixed with alcohol (AmEDs). Methods: The study involved a specially designed questionnaire, which was completed by 707 students, 14.3 years of age on average, attending secondary sports schools. Results: EDs were consumed by 69% of the young athletes, 17% of whom drank EDs quite often: every day or 1–3 times a week.
    [Show full text]
  • G Protein-Coupled Receptors
    S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors. British Journal of Pharmacology (2015) 172, 5744–5869 THE CONCISE GUIDE TO PHARMACOLOGY 2015/16: G protein-coupled receptors Stephen PH Alexander1, Anthony P Davenport2, Eamonn Kelly3, Neil Marrion3, John A Peters4, Helen E Benson5, Elena Faccenda5, Adam J Pawson5, Joanna L Sharman5, Christopher Southan5, Jamie A Davies5 and CGTP Collaborators 1School of Biomedical Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK, 2Clinical Pharmacology Unit, University of Cambridge, Cambridge, CB2 0QQ, UK, 3School of Physiology and Pharmacology, University of Bristol, Bristol, BS8 1TD, UK, 4Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK, 5Centre for Integrative Physiology, University of Edinburgh, Edinburgh, EH8 9XD, UK Abstract The Concise Guide to PHARMACOLOGY 2015/16 provides concise overviews of the key properties of over 1750 human drug targets with their pharmacology, plus links to an open access knowledgebase of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. The full contents can be found at http://onlinelibrary.wiley.com/doi/ 10.1111/bph.13348/full. G protein-coupled receptors are one of the eight major pharmacological targets into which the Guide is divided, with the others being: ligand-gated ion channels, voltage-gated ion channels, other ion channels, nuclear hormone receptors, catalytic receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading.
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • Molecular Genetics of Alzheimer's Disease
    DkYb[_Y7Y_ZiWdZCeb[YkbWh8_ebe]o 23 I[h_[i;Z_jeh >$@$=heii Institut für Biochemie Biozentrum Am Hubland 97074 Würzburg Germany Dieter B. Wildenauer (Ed.) Molecular Biology of Neuropsychiatric Disorders With 15 Figures and 8 Tables Editor Dieter B. Wildenauer Graylands Hospital Center for Clinical Research in Neuropsychiatry (CCRN) Claremont WA 6910 Australia ISBN 978-3-540-85382-4 e-ISBN 978-3-540-85383-1 ISSN 0933-1891 Library of Congress Control Number: 2008933566 © 2009 Springer-Verlag Berlin Heidelberg This work is subject to copyright. All rights are reserved, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilm or in any other way, and storage in data banks. Duplication of this publication or parts thereof is permitted only under the provisions of the German Copyright Law of September 9, 1965, in its current version, and permission for use must always be obtained from Springer. Violations are liable to prosecution under the German Copyright Law. The use of general descriptive names, registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. Cover design: Boekhorst Design BV, The Netherlands Printed on acid-free paper 9 8 7 6 5 4 3 2 1 springer.com Preface The intention of this book is to give an overview about ongoing research into molecular causes for disorders that affect the human brain. These disorders afflict mainly human behavior and are, since borders between “normal” and “abnormal” behaviors are continuous and hard to define, not always easy to diagnose.
    [Show full text]
  • Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
    US 20190192440A1 (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0192440 A1 LI (43 ) Pub . Date : Jun . 27 , 2019 ( 54 ) ORAL DRUG DOSAGE FORM COMPRISING Publication Classification DRUG IN THE FORM OF NANOPARTICLES (51 ) Int . CI. A61K 9 / 20 (2006 .01 ) ( 71 ) Applicant: Triastek , Inc. , Nanjing ( CN ) A61K 9 /00 ( 2006 . 01) A61K 31/ 192 ( 2006 .01 ) (72 ) Inventor : Xiaoling LI , Dublin , CA (US ) A61K 9 / 24 ( 2006 .01 ) ( 52 ) U . S . CI. ( 21 ) Appl. No. : 16 /289 ,499 CPC . .. .. A61K 9 /2031 (2013 . 01 ) ; A61K 9 /0065 ( 22 ) Filed : Feb . 28 , 2019 (2013 .01 ) ; A61K 9 / 209 ( 2013 .01 ) ; A61K 9 /2027 ( 2013 .01 ) ; A61K 31/ 192 ( 2013. 01 ) ; Related U . S . Application Data A61K 9 /2072 ( 2013 .01 ) (63 ) Continuation of application No. 16 /028 ,305 , filed on Jul. 5 , 2018 , now Pat . No . 10 , 258 ,575 , which is a (57 ) ABSTRACT continuation of application No . 15 / 173 ,596 , filed on The present disclosure provides a stable solid pharmaceuti Jun . 3 , 2016 . cal dosage form for oral administration . The dosage form (60 ) Provisional application No . 62 /313 ,092 , filed on Mar. includes a substrate that forms at least one compartment and 24 , 2016 , provisional application No . 62 / 296 , 087 , a drug content loaded into the compartment. The dosage filed on Feb . 17 , 2016 , provisional application No . form is so designed that the active pharmaceutical ingredient 62 / 170, 645 , filed on Jun . 3 , 2015 . of the drug content is released in a controlled manner. Patent Application Publication Jun . 27 , 2019 Sheet 1 of 20 US 2019 /0192440 A1 FIG .
    [Show full text]
  • A Guide to Obesity and the Metabolic Syndrome
    A GUIDE TO OBESITY AND THE METABOLIC SYNDROME ORIGINS AND TREAT MENT GEORG E A. BRA Y Louisiana State University, Baton Rouge, USA Boca Raton London New York CRC Press is an imprint of the Taylor & Francis Group, an informa business © 2011 by Taylor and Francis Group, LLC CRC Press Taylor & Francis Group 6000 Broken Sound Parkway NW, Suite 300 Boca Raton, FL 33487-2742 © 2011 by Taylor and Francis Group, LLC CRC Press is an imprint of Taylor & Francis Group, an Informa business No claim to original U.S. Government works Printed in the United States of America on acid-free paper 10 9 8 7 6 5 4 3 2 1 International Standard Book Number: 978-1-4398-1457-4 (Hardback) This book contains information obtained from authentic and highly regarded sources. Reasonable efforts have been made to publish reliable data and information, but the author and publisher cannot assume responsibility for the valid- ity of all materials or the consequences of their use. The authors and publishers have attempted to trace the copyright holders of all material reproduced in this publication and apologize to copyright holders if permission to publish in this form has not been obtained. If any copyright material has not been acknowledged please write and let us know so we may rectify in any future reprint. Except as permitted under U.S. Copyright Law, no part of this book may be reprinted, reproduced, transmitted, or uti- lized in any form by any electronic, mechanical, or other means, now known or hereafter invented, including photocopy- ing, microfilming, and recording, or in any information storage or retrieval system, without written permission from the publishers.
    [Show full text]
  • AHRQ Healthcare Horizon Scanning System – Status Update Horizon
    AHRQ Healthcare Horizon Scanning System – Status Update Horizon Scanning Status Update: April 2015 Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 540 Gaither Road Rockville, MD 20850 www.ahrq.gov Contract No. HHSA290-2010-00006-C Prepared by: ECRI Institute 5200 Butler Pike Plymouth Meeting, PA 19462 April 2015 Statement of Funding and Purpose This report incorporates data collected during implementation of the Agency for Healthcare Research and Quality (AHRQ) Healthcare Horizon Scanning System by ECRI Institute under contract to AHRQ, Rockville, MD (Contract No. HHSA290-2010-00006-C). The findings and conclusions in this document are those of the authors, who are responsible for its content, and do not necessarily represent the views of AHRQ. No statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services. A novel intervention may not appear in this report simply because the System has not yet detected it. The list of novel interventions in the Horizon Scanning Status Update Report will change over time as new information is collected. This should not be construed as either endorsements or rejections of specific interventions. As topics are entered into the System, individual target technology reports are developed for those that appear to be closer to diffusion into practice in the United States. A representative from AHRQ served as a Contracting Officer’s Technical Representative and provided input during the implementation of the horizon scanning system. AHRQ did not directly participate in the horizon scanning, assessing the leads or topics, or provide opinions regarding potential impact of interventions.
    [Show full text]
  • Treatment of Problem Cocaine Use a Review of the Literature the of Review a Literature
    TREATMENT OF PROBLEM COCAINE USE COCAINE PROBLEM OF TREATMENT A REVIEW OF THE LITERATURE LITERATURE REVIEW ISBN 92-9168-274-8 ISBN EMCDDA literature reviews Treatment of problem cocaine use: a review of the literature EMCDDA literature reviews — Treatment of problem cocaine use Acknowledgements This literature review is based on a consultant report by Christian Haasen and Katja Thane, Institut für Interdisziplinäre Sucht- und Drogenforschung (ISD), Hamburg, at the Zentrum für Interdisziplinäre Suchtforschung (ZIS) of the University of Hamburg (Service Contract CT.06.RES.144.1.0). EMCDDA project managers: Dagmar Hedrich and Alessandro Pirona. Other contributors to this project included Prepress Projects, Rosemary de Sousa and Peter Thomas. Cataloguing data European Monitoring Centre for Drugs and Drug Addiction, 2007 EMCDDA Literature reviews — Treatment of problem cocaine use: a review of the literature Lisbon: European Monitoring Centre for Drugs and Drug Addiction 2007 — 50 pp. — 21 x 29.7 cm Language: EN Catalogue Number: TD-XB-06-001-EN-N ISBN: 92-9168-274-8 ISSN: 1725-0579 © European Monitoring Centre for Drugs and Drug Addiction, 2007. Reproduction is authorised provided the source is acknowledged. Rua da Cruz de Santa Apolónia 23-25, PT-1149-045 Lisbon, Portugal Tel: (+351) 21 811 3000 Fax: (+351) 21 813 1711 [email protected] http://www.emcdda.europa.eu 3 EMCDDA literature reviews — Treatment of problem cocaine use List of abbreviations ADHD attention deficit hyperactivity disorder BBD blood-borne disease CA Cocaine Anonymous
    [Show full text]
  • G Protein-Coupled Receptors
    Alexander, S. P. H., Christopoulos, A., Davenport, A. P., Kelly, E., Marrion, N. V., Peters, J. A., Faccenda, E., Harding, S. D., Pawson, A. J., Sharman, J. L., Southan, C., Davies, J. A. (2017). THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: G protein-coupled receptors. British Journal of Pharmacology, 174, S17-S129. https://doi.org/10.1111/bph.13878 Publisher's PDF, also known as Version of record License (if available): CC BY Link to published version (if available): 10.1111/bph.13878 Link to publication record in Explore Bristol Research PDF-document This is the final published version of the article (version of record). It first appeared online via Wiley at https://doi.org/10.1111/bph.13878 . Please refer to any applicable terms of use of the publisher. University of Bristol - Explore Bristol Research General rights This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/ S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2017/18: G protein-coupled receptors. British Journal of Pharmacology (2017) 174, S17–S129 THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: G protein-coupled receptors Stephen PH Alexander1, Arthur Christopoulos2, Anthony P Davenport3, Eamonn Kelly4, Neil V Marrion4, John A Peters5, Elena Faccenda6, Simon D Harding6,AdamJPawson6, Joanna L Sharman6, Christopher Southan6, Jamie A Davies6 and CGTP Collaborators 1 School of Life Sciences,
    [Show full text]